Combination of balstilimab plus zalifrelimab doubles responses in 2l cervical cancer in data to be presented at esmo

Lexington, mass., sept. 16, 2021 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented final results from the bal/zal combination study at the european society for medical oncology (esmo) virtual conference 2021 in an abstract titled balstilimab (anti-pd-1) in combination with zalifrelimab (anti-ctla-4): final results from a phase 2 study in patients (pts) with recurrent/metastatic (r/m) cervical cancer (cc).
AGEN Ratings Summary
AGEN Quant Ranking